Objective To provide references and suggestions for the future innovation model for traditional Chinese medicine (TCM) enterprises,and to promote the modernization and the innovative changes of these enterprises throu...Objective To provide references and suggestions for the future innovation model for traditional Chinese medicine (TCM) enterprises,and to promote the modernization and the innovative changes of these enterprises through identifying the incremental innovation and analyze how different types of complementary assets adjust the relationship between incremental innovation and enterprise performance.Methods Pooled OLS model was used to make an empirical study on the relationship between the incremental innovation and the performance of the listed TCM enterprises and the regulating effect of different types of complementary assets.Results and Conclusion As far as the current complementary assets are concerned,manufacturing-specific complementary assets and marketspecific complementary assets are positively affecting the incremental innovation of enterprise performance,while manpower-specific complementary assets do not have a regulatory role.TCM enterprises should adhere to the mode of incremental innovation and use their own complementary assets to improve enterprise performance.展开更多
文摘目的探讨应用聚乙二醇化干扰素α(Peg-ⅠFNα)联合利巴韦林(RBV)治疗基因1/6型慢性丙型肝炎(CHC)患者的临床疗效。方法随机将246例慢性丙型肝炎(CHC)患者分为观察组123例和对照组123例,分别接受Peg-ⅠFNα-2b 80μg或Peg-ⅠFNα-2a 180μg皮下注射,1次/w,两组均同时口服利巴韦林,治疗48 w,随访24 w。采用罗氏公司COBAS Taqman HCV实时定量PCR试剂检测血清HCV RNA,采用Abbott Real Time HCV Genotype Ⅱ试剂检测HCV基因型。结果观察组和对照组基线基因1型感染者分别为104例(84.6%)和108例(87.8%),基因6型感染者分别为19例(15.4%)和15例(12.2%,P>0.05),血清HCV RNA水平分别为(7.17±0.89) lg copies/ml和(7.19±0.88) lg copies/ml,白细胞计数分别为(6.6±1.3)×10~9/L和(6.6±1.5)×10~9/L,血小板计数分别为(154.1±21.1)×10~9/L和(157.2±19.2)×10~9/L,血清ALT水平分别为(83.4±26.3) U/L和(80.3±29.4)U/L,均无显著性相差(P>0.05);观察组快速病毒学应答率(RVR)、早期病毒学应答率(EVR)、治疗结束时病毒学应答率(ETVR)和持续病毒学应答率(SVR)分别为45.5%、82.1%、83.7%和85.4%,与对照组的43.1%、78.9%、79.7%和78.0%比,无显著性差异(P>0.05),两组停药后复发率分别为14.6%和22.0%,也无显著性相差(P>0.05);在治疗过程中,观察组与对照组发热(58.5%对61.0%)、肌肉酸痛(48.8%对51.2%)、乏力(41.5%对44.7%)、头痛(30.9%对34.1%)、厌食(25.2%对30.1%)、脱发(26.8%对30.9%)、失眠(20.3%对25.2%)、白细胞下降(27.6%对31.7%)、红细胞下降(23.6%对28.5%)、血小板下降(13.8%对17.9%)和血清T3/T4/TSH异常(8.9%对10.6%)等不良反应发生率比较,均无显著性差异(P>0.05)。结论应用Peg-ⅠFNα-2b或Peg-ⅠFNα-2a治疗基因1/6型CHC患者,疗效较好,且两种干扰素治疗效果相当,安全性较好,值得临床应用。
文摘Objective To provide references and suggestions for the future innovation model for traditional Chinese medicine (TCM) enterprises,and to promote the modernization and the innovative changes of these enterprises through identifying the incremental innovation and analyze how different types of complementary assets adjust the relationship between incremental innovation and enterprise performance.Methods Pooled OLS model was used to make an empirical study on the relationship between the incremental innovation and the performance of the listed TCM enterprises and the regulating effect of different types of complementary assets.Results and Conclusion As far as the current complementary assets are concerned,manufacturing-specific complementary assets and marketspecific complementary assets are positively affecting the incremental innovation of enterprise performance,while manpower-specific complementary assets do not have a regulatory role.TCM enterprises should adhere to the mode of incremental innovation and use their own complementary assets to improve enterprise performance.
